| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 151, 1767-1774, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
AK El-Naggar, S Lai, G Clayman, JK Lee, MA Luna, H Goepfert and JG Batsakis
Department of Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston 77030, USA.
We studied 11 head and neck squamous carcinoma (HNSC) cell lines and 46 primary tumors for p16 gene status by protein, mRNA, and DNA genetic/epigenetic analyses to determine the incidence, the mechanism(s), and the potential biological significance of its inactivation. Of the 11 cell lines, only 1 showed intact p16 and 10 lacked its protein and mRNA; DNA analysis of these 10 cell lines showed 2 homozygous deletions, 6 methylations at exon 1 and 2, and 2 with no detectable abnormalities. In primary tumors, 16 (34.7%) of the 46 showed detectable p16 protein and mRNA; of these, 12 had no DNA abnormalities and 4 had only exon 2 methylation. Loss of p16 expression was found in three tumors with concurrent mutation at exon 2 and methylation at exon 2 (two) and both 1 and 2 (one). Of the 30 tumors that lacked p16 protein, 27 also lacked mRNA, 1 had detectable p16 mRNA, and 2 failed RT-PCR amplification. Twenty-two of the thirty tumors showed DNA alterations and eight manifested no abnormalities; DNA alterations comprised 6 homozygous deletions, 2 concurrent mutations and methylation of exon 2, and 13 with methylation at exon 1 and exons 1 and 2 (12 with methylation only and 1 with mutation) at exon 1. Except for patients' gender (P = 0.02), no significant correlation between p16 and clinicopathological factors was observed. We conclude that in HNSC 1) intragenic p16 alterations are infrequent events, 2) methylation of exon 1 constitutes a common mechanism in silencing the p16 gene, 3) p16 inactivation may play an important role in the early development and progression of HNSC, and 4) no association between p16 alterations and conventional clinicopathological factors was noted in this cohort.
This article has been cited by other articles:
 |
|
 |
|
  M. J. Worsham, K. M. Chen, V. Meduri, A. O. H. Nygren, A. Errami, J. P. Schouten, and M. S. Benninger Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, June 1, 2006; 132(6): 668 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Li, A.-M. Hui, L. Sun, K. Hasegawa, G. Torzilli, M. Minagawa, T. Takayama, and M. Makuuchi p16INK4A Hypermethylation Is Associated with Hepatitis Virus Infection, Age, and Gender in Hepatocellular Carcinoma Clin. Cancer Res., November 15, 2004; 10(22): 7484 - 7489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Maruya, J.-P. J. Issa, R. S. Weber, D. I. Rosenthal, J. C. Haviland, R. Lotan, and A. K. El-Naggar Differential Methylation Status of Tumor-Associated Genes in Head and Neck Squamous Carcinoma: Incidence and Potential Implications Clin. Cancer Res., June 1, 2004; 10(11): 3825 - 3830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Klussmann, E. Gultekin, S. J. Weissenborn, U. Wieland, V. Dries, H. P. Dienes, H. E. Eckel, H. J. Pfister, and P. G. Fuchs Expression of p16 Protein Identifies a Distinct Entity of Tonsillar Carcinomas Associated with Human Papillomavirus Am. J. Pathol., March 1, 2003; 162(3): 747 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Chaturvedi, M. Cesnjaj, P. Bacon, J. Panella, D. Choubey, M. O. Diaz, and B. J. Nickoloff Role of INK4a/Arf Locus-Encoded Senescent Checkpoints Activated in Normal and Psoriatic Keratinocytes Am. J. Pathol., January 1, 2003; 162(1): 161 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Geisler, A. F. Olshan, M. C. Weissler, J. Cai, W. K. Funkhouser, J. Smith, and K. Vick p16 and p53 Protein Expression as Prognostic Indicators of Survival and Disease Recurrence from Head and Neck Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3445 - 3453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Kresty, S. R. Mallery, T. J. Knobloch, H. Song, M. Lloyd, B. C. Casto, and C. M. Weghorst Alterations of p16INK4a and p14ARF in Patients with Severe Oral Epithelial Dysplasia Cancer Res., September 15, 2002; 62(18): 5295 - 5300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zheng, H. Shen, E. M. Sturgis, L.-E Wang, S. Shete, M. R. Spitz, and Q. Wei Haplotypes of Two Variants in p16 (CDKN2/MTS-1/INK4a) Exon 3 and Risk of Squamous Cell Carcinoma of the Head and Neck: A Case-Control Study Cancer Epidemiol. Biomarkers Prev., July 1, 2002; 11(7): 640 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koenig, S. R. Bianco, S. Fosmire, J. Wojcieszyn, and J. F. Modiano Expression and Significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN Tumor Suppressors in Canine Melanoma Vet. Pathol., July 1, 2002; 39(4): 458 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Lee, J.-C. Soria, K. A. Hassan, A. K. El-Naggar, X. Tang, D. D. Liu, W. K. Hong, and L. Mao Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer Arch Otolaryngol Head Neck Surg, December 1, 2001; 127(12): 1441 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. El-Naggar, L. Mao, G. Staerkel, M. M. Coombes, S. L. Tucker, M. A. Luna, G. L. Clayman, S. Lippman, and H. Goepfert Genetic Heterogeneity in Saliva from Patients with Oral Squamous Carcinomas: Implications in Molecular Diagnosis and Screening J. Mol. Diagn., November 1, 2001; 3(4): 164 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. El-Naggar, S. Lai, G. L. Clayman, B. Mims, S. M. Lippman, M. Coombes, M. A. Luna, and G. Lozano p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas Carcinogenesis, May 1, 2001; 22(5): 729 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Serrano, S. U. Goebel, P. L. Peghini, I. A. Lubensky, F. Gibril, and R. T. Jensen Alterations in the p16INK4a/CDKN2A Tumor Suppressor Gene in Gastrinomas J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4146 - 4156. [Abstract] [Full Text]
|
|
|
|
|
|
T. Nakashima and G. L. Clayman Antisense Inhibition of Cyclin D1 in Human Head and Neck Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, August 1, 2000; 126(8): 957 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lai, H. Goepfert, A. M. Gillenwater, M. A. Luna, and A. K. El-Naggar Loss of Imprinting and Genetic Alterations of the Cyclin-dependent Kinase Inhibitor p57KIP2 Gene in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., August 1, 2000; 6(8): 3172 - 3176. [Abstract] [Full Text]
|
|
|
|
|
|
E. R. Sauter, M. Herlyn, S.-C. Liu, S. Litwin, and J. A. Ridge Prolonged Response to Antisense Cyclin D1 in a Human Squamous Cancer Xenograft Model Clin. Cancer Res., February 1, 2000; 6(2): 654 - 660. [Abstract] [Full Text]
|
|
|
|
|
|
E. R. Sauter, M. Nesbit, S. Litwin, A. J. P. Klein-Szanto, S. Cheffetz, and M. Herlyn Antisense Cyclin D1 Induces Apoptosis and Tumor Shrinkage in Human Squamous Carcinomas Cancer Res., October 1, 1999; 59(19): 4876 - 4881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Chaturvedi, J.-Z. Qin, M. F. Denning, D. Choubey, M. O. Diaz, and B. J. Nickoloff Apoptosis in Proliferating, Senescent, and Immortalized Keratinocytes J. Biol. Chem., August 13, 1999; 274(33): 23358 - 23367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Gorgoulis, P. Zacharatos, A. Kotsinas, T. Liloglou, A. Kyroudi, M. Veslemes, A. Rassidakis, T. D. Halazonetis, J. K. Field, and C. Kittas Alterations of the p16-pRb Pathway and the Chromosome Locus 9p21–22 in Non-Small-Cell Lung Carcinomas : Relationship with p53 and MDM2 Protein Expression Am. J. Pathol., December 1, 1998; 153(6): 1749 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Nickoloff, V. Chaturvedi, P. Bacon, J.-Z. Qin, M. F. Denning, and M. O. Diaz Id-1 Delays Senescence but Does Not Immortalize Keratinocytes J. Biol. Chem., September 1, 2000; 275(36): 27501 - 27504. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
